Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHA:688566)
27.88
-0.06 (-0.21%)
Feb 4, 2026, 10:14 AM CST
SHA:688566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 957.76 | 896.53 | 860.93 | 654.73 | 509.69 | 565.97 | |
Revenue Growth (YoY) | 7.96% | 4.13% | 31.49% | 28.46% | -9.94% | 4.32% |
Cost of Revenue | 100.43 | 95.26 | 97.18 | 76.17 | 62.12 | 64.06 |
Gross Profit | 857.33 | 801.28 | 763.76 | 578.56 | 447.57 | 501.91 |
Selling, General & Admin | 537.92 | 458.54 | 459.86 | 361.56 | 304.65 | 326.75 |
Research & Development | 37.7 | 38.65 | 55.77 | 55.18 | 29.28 | 33.55 |
Other Operating Expenses | 14.78 | 12.98 | 10.47 | 9.24 | 9.1 | 9.89 |
Operating Expenses | 590.1 | 512.43 | 533.31 | 426.71 | 341.26 | 373.28 |
Operating Income | 267.22 | 288.85 | 230.44 | 151.85 | 106.32 | 128.63 |
Interest Expense | -0.23 | -0.13 | -0.11 | -0.38 | - | - |
Interest & Investment Income | 5.75 | 5.4 | 12.02 | 17.77 | 21.64 | 19.51 |
Other Non Operating Income (Expenses) | 0.45 | -0.11 | -0.14 | -0.07 | -0.11 | -0.11 |
EBT Excluding Unusual Items | 273.2 | 294.01 | 242.22 | 169.18 | 127.85 | 148.02 |
Gain (Loss) on Sale of Investments | -1.2 | -1.05 | -1.9 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | -0.01 | - | 0 |
Asset Writedown | -42.24 | -42.24 | - | - | - | - |
Other Unusual Items | 50.96 | 2.65 | 7.16 | 5.37 | 4.71 | 0.51 |
Pretax Income | 280.72 | 253.36 | 247.48 | 174.53 | 132.56 | 148.53 |
Income Tax Expense | 40.19 | 34.39 | 28.71 | 20.27 | 18.22 | 18.67 |
Earnings From Continuing Operations | 240.53 | 218.98 | 218.77 | 154.26 | 114.35 | 129.86 |
Minority Interest in Earnings | 1.14 | 0.35 | 0.32 | 0.4 | 0.55 | -0.14 |
Net Income | 241.67 | 219.33 | 219.09 | 154.67 | 114.9 | 129.72 |
Net Income to Common | 241.67 | 219.33 | 219.09 | 154.67 | 114.9 | 129.72 |
Net Income Growth | 1.29% | 0.11% | 41.65% | 34.61% | -11.42% | 14.88% |
Shares Outstanding (Basic) | 199 | 194 | 187 | 186 | 188 | 168 |
Shares Outstanding (Diluted) | 199 | 194 | 187 | 186 | 188 | 168 |
Shares Change (YoY) | 4.39% | 3.65% | 0.49% | -1.07% | 11.81% | 20.85% |
EPS (Basic) | 1.21 | 1.13 | 1.17 | 0.83 | 0.61 | 0.77 |
EPS (Diluted) | 1.21 | 1.13 | 1.17 | 0.83 | 0.61 | 0.77 |
EPS Growth | -2.97% | -3.42% | 40.96% | 36.07% | -20.78% | -4.94% |
Free Cash Flow | 74.53 | 40.76 | -197.87 | -141.98 | 66.77 | 93.68 |
Free Cash Flow Per Share | 0.37 | 0.21 | -1.06 | -0.76 | 0.35 | 0.56 |
Dividend Per Share | 0.520 | 0.780 | - | 0.480 | 0.480 | 0.480 |
Gross Margin | 89.51% | 89.38% | 88.71% | 88.37% | 87.81% | 88.68% |
Operating Margin | 27.90% | 32.22% | 26.77% | 23.19% | 20.86% | 22.73% |
Profit Margin | 25.23% | 24.46% | 25.45% | 23.62% | 22.54% | 22.92% |
Free Cash Flow Margin | 7.78% | 4.55% | -22.98% | -21.68% | 13.10% | 16.55% |
EBITDA | 277.37 | 299.45 | 241.65 | 164.6 | 119.3 | 141.93 |
EBITDA Margin | 28.96% | 33.40% | 28.07% | 25.14% | 23.41% | 25.08% |
D&A For EBITDA | 10.15 | 10.6 | 11.2 | 12.75 | 12.98 | 13.3 |
EBIT | 267.22 | 288.85 | 230.44 | 151.85 | 106.32 | 128.63 |
EBIT Margin | 27.90% | 32.22% | 26.77% | 23.19% | 20.86% | 22.73% |
Effective Tax Rate | 14.32% | 13.57% | 11.60% | 11.62% | 13.74% | 12.57% |
Revenue as Reported | 957.76 | 896.53 | 860.93 | 654.73 | 509.69 | 565.97 |
Advertising Expenses | - | - | - | 153.2 | 121.29 | 142.98 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.